trial

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

NCTId NCT02411526
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 60 (actual)
Sponsored by Zogenix, Inc.
Primary completion 2015-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
60 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2015-02
Primary completion
2015-09
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Zogenix, Inc.Lead Sponsor

Investigators

1
David P Walling, PhDPrincipal Investigator

Sites

1 total
Long Beach, United States

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE1
Primary Completion Date
2015-09
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Zogenix, Inc.
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
David P Walling, PhD
person